Investor Relations

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway.

Eton has a diversified pipeline of product candidates under development across various liquid dosage forms, including injectables, oral liquids, and ophthalmics.

Volume :

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
October 16, 2020
DEER PARK, Ill. , Oct. 16, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously announced offering of 3,220,000
October 15, 2020
- Application Assigned a PDUFA Date of May 29, 2021 DEER PARK, Ill. , Oct. 15, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S.
October 14, 2020
DEER PARK, Ill. , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the pricing of an underwritten public offering of 2,800,000

Eton
Latest Event

Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
More events are coming soon.